OBT202

OBT202 is an investigational antibody-drug conjugate (ADC) being developed by Oxford BioTherapeutics for the treatment of cancer. Currently in the discovery stage, OBT202 is designed to utilize a monoclonal antibody to specifically target a tumor-associated antigen and deliver a potent cytotoxic payload directly into the cancer cells, minimizing systemic toxicity. The specific molecular target and the nature of the cytotoxic payload have not yet been disclosed by the developer. The program originates from the company's proprietary OGAP® (Oxford Genome Anatomy Project) platform, which identifies novel targets for oncology therapeutics.